THIEBAUD, P.; GARBAY, B.; AUGUSTE, P.; LE SENECHAL, C.; MACIEJEWSKA, Z.; FEDOU, S.; GAUTHEREAU, X.; COSTAGLIOLI, Patricia; THEZE, N.

doi:10.1016/j.peptides.2016.06.008

Métadonnées

Afficher la notice complète

Licence d’utilisation du document

Langue

Article de revue

Ce document a été publié dans

Peptides. 2016, vol. 83, p. 21-28

Résumé en anglais

Besides its widely described function in the innate immune response, no other clear physiological function has been attributed so far to the Liver-Expressed-Antimicrobial-Peptide 2 (LEAP2). We used the Xenopus embryo model to investigate potentially new functions for this peptide. We identified the amphibian leap2 gene which is highly related to its mammalian orthologues at both structural and sequence levels. The gene is expressed in the embryo mostly in the endoderm-derived tissues. Accordingly it is induced in pluripotent animal cap cells by FGF, activin or a combination of vegT/beta-catenin. Modulating leap2 expression level by gain-of-function strategy impaired normal embryonic development. When over-expressed in pluripotent embryonic cells derived from blastula animal cap explant, leap2 stimulated FGF while it reduced the activin response. Finally, we demonstrate that LEAP2 blocks FGF-induced migration of HUman Vascular Endothelial Cells (HUVEC). Altogether these findings suggest a model in which LEAP2 could act at the extracellular level as a modulator of FGF and activin signals, thus opening new avenues to explore it in relation with cellular processes such as cell differentiation and migration. (C) 2016 Elsevier Inc. All rights reserved.< Réduire

Métadonnées

Partager cette publication !

Licence d’utilisation du document

Overexpression of Leap2 impairs Xenopus embryonic development and modulates FGF and activin signals

Langue

Ce document a été publié dans

Résumé en anglais

URI

DOI

Unités de recherche